Prevention of iron loading in transfusion-dependent thalassaemia

Area of Science:

• Hematology
• Pharmacology
• Pediatrics

Background:

• Homozygous beta-thalassaemia patients often require frequent blood transfusions.
• Transfusion therapy leads to iron overload, necessitating chelation treatment.
• Desferrioxamine (D.F.) is a key chelating agent used in managing iron overload.

Purpose of the Study:

• To compare urinary iron excretion following intramuscular (i.m.) versus subcutaneous (s.c.) desferrioxamine (D.F.) administration.
• To assess the efficacy of D.F. chelation in achieving iron balance in young beta-thalassaemia patients.
• To evaluate the potential for preventing iron loading with early chelation therapy.

Main Methods:

• Sixteen homozygous beta-thalassaemia patients (10 months to 23 years) received single i.m. bolus injections or 12-hour s.c. infusions of D.F.
• Urinary iron excretion was measured after D.F. administration.
• Iron balance was assessed based on iron excretion and estimated iron load.

Main Results:

• Subcutaneous (s.c.) infusions of D.F. resulted in significantly greater iron loss compared to identical intramuscular (i.m.) doses across all age groups.
• In children under 6 years with a low transfusion iron load (<10 g), D.F. s.c. infusions (0.5-1 g) achieved iron balance in 8 out of 9 patients.
• Age and administration route influenced iron excretion efficacy.

Conclusions:

• Subcutaneous desferrioxamine (D.F.) infusion is a more effective route for iron excretion than intramuscular injection in beta-thalassaemia.
• Early initiation of an appropriate desferrioxamine (D.F.) chelation regimen in childhood may prevent progressive iron loading.
• Chelation therapy is crucial for managing transfusion-dependent beta-thalassaemia and preventing complications of iron overload.